APA (7th ed.) Citation

JW, P., JR, C., SR, C., MJ, K., YJ, H., EH, K., . . . EB, L. (2023). Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis & rheumatology (Hoboken, N.J.), 75(11), 2036. https://doi.org/10.1002/art.42541

Chicago Style (17th ed.) Citation

JW, Park, Curtis JR, Choi SR, Kim MJ, Ha YJ, Kang EH, Lee YJ, and Lee EB. "Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab." Arthritis & Rheumatology (Hoboken, N.J.) 75, no. 11 (2023): 2036. https://doi.org/10.1002/art.42541.

MLA (9th ed.) Citation

JW, Park, et al. "Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab." Arthritis & Rheumatology (Hoboken, N.J.), vol. 75, no. 11, 2023, p. 2036, https://doi.org/10.1002/art.42541.